The role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice

Publish Year: 1395
نوع سند: مقاله ژورنالی
زبان: English
View: 209

This Paper With 9 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJBMS-19-2_009

تاریخ نمایه سازی: 30 مهر 1400

Abstract:

Objective(s):Development of new generation of vaccines against leishmaniasis is possible because long-term protection is usually seen after recovery from cutaneous leishmaniasis. ISCOMATRIX is particulate antigen delivery system composed of antigen, cholesterol, phospholipid and saponin. In this study, the role of ISCOMATRIX bilayer composition made by different phase transition temperature (Tc) to induce a type of immune response and protection against leishmaniasis was assessed. Materials and Methods:ISCOMATRIX formulations with different bilayer compositions consisting of EPC (Tc <۰ ◦C), DMPC (Tc ۲۳ ◦C) and DSPC (Tc ۵۴ ◦C) were prepared. Different ISCOMATRIX formulations were mixed with soluble Leishmania antigens (SLA). BALB/c mice were immunized subcutaneously, three times with ۲-week intervals.  As criteria for protection, footpads swelling, parasite burden, determination of IgG isotypes and the level of IFN-γ and IL-۴ were assessed. Results: Although the groups of mice immunized with ISCOMATRIX DMPC or ISCOMATRIX DSPC showed the smallest footpad swelling and least parasite burden compared with the buffer group, the difference was not significant. Moreover, the highest level of IFN- γ and IL-۴ was observed in the splenocytes of mice immunized with ISCOMATRIX DMPC or ISCOMATRIX DSPC, respectively. After challenge, the mice immunized with ISCOMATRIX DSPC showed the highest elevation of IgG, IgG۱ and IgG۲a antibodies (P<۰.۰۱) compared with control group. However, our results indicated that ISCOMATRIX EPC, DMPC or DSPC generated a mixed Th۱/Th۲ response that was not protective. Conclusion: Our results showed that the adjuvanticity of prepared ISCOMATRIX doesn’t influence with different phospholipids at least in our mice model.

Authors

Ahmad Mehravaran

Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Mahmoud Reza Jaafari

Biotechnology Research Center, Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Seyed Amir Jalali

Immunology Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Ali Khamesipour

Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran

Reza Ranjbar

Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

Mansure Hojatizade

Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Ali Badiee

Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • World Health Organization. Control of the leishmaniases. World Health Organ. ...
  • World Health Organization. Control of the Leishmaniases. Report of a ...
  • Alvar J, Croft S, Kaye P, Khamesipour A, Sundar S, ...
  • Thakur CP, Kumar K. Post Kala-azar dermal leishmaniasis: a neglected ...
  • Bryceson A. A policy for leishmaniasis with respect to the ...
  • Croft SL, Coombs GH. Leishmaniasis current chemotherapy and recent advances ...
  • Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, ...
  • Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance ...
  • Grencis RK. Th۲-mediated host protective immunity to intestinal nematode infections. ...
  • Modabber F. Vaccines against leishmaniasis. Ann Trop Med Parasitol ۱۹۹۵; ...
  • Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, ...
  • Modabber F, Coler R, Reed SG. Vaccines against Leishmania. In: ...
  • Mutiso JM, Macharia JC, Mutisya RM, Taracha E. Subcutaneous immunization ...
  • Copland MJ, Rades T, Davies NM, Baird MA. Lipid based ...
  • Badiee A, Heravi SV, Khamesipour A, Jaafari MR. Micro/nanoparticle adjuvants ...
  • Hong-Xiang S, Yong X, Yi-Ping Y. ISCOMs and ISCOMATRIX TM ...
  • Rimmelzwaan GF, Osterhaus ADME. A novel generation of viral vaccines ...
  • Lövgren K, Morein B, Osterhaus A. ISCOM technology-based Matrix M™ ...
  • Sanders MT, Brown LE, Deliyannis G, Pearse MJ. ISCOM-based vaccines: ...
  • Sjölander A, Drane D, Maraskovsky E, Scheerlinck JP, Suhrbier A, ...
  • Barr IG, Sjolander A, Cox JC. ISCOMs and other saponin ...
  • Sjolander A, Cox JC, Barr IG. ISCOMs: an adjuvant with ...
  • Cox JC. Drane D, Suhrbier A. Immunogenic complex and methods ...
  • Behboudi S, Morein B, Vilacres-Eriksson M. In vitro activation of ...
  • Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F. ...
  • Scott P, Pearce E, Natovitz P, Sher A. Vaccination against ...
  • Bainor A, Chang L, McQuade TJ, Webb B, Gestwicki JE. ...
  • Liang MT, Toth I, Davies NM. A novel method for ...
  • Jaafari MR, Ghafarian A, Farrokh-Gisour A, Samiei A, Kheiri MT, ...
  • Titus RG, Marchand M, Boon T, Louis JA. A limiting ...
  • Badiee A, Jaafari MR, Khamesipour A. Leishmania major: immune response ...
  • Taswell C. Limiting dilution assays for the determination of immuno ...
  • Jaafari MR, Badiee A, Khamesipour A, Samiei A, Soroush D, ...
  • Golali E, Jaafari MR, Khamesipour A, Abbasi A, Saberi Z, ...
  • Hejazi H, Tasbihi M, Jaafari M, Badiee A, Pestechian N, ...
  • Vanloubbeeck Y, Jones DE. The immunology of Leishmania infection and ...
  • Drane D, Gittleson C, Boyle J, Maraskovsky E. ISCOMATRIX adjuvant ...
  • Silva A, Mount A, Krstevska K, Pejoski D, Hardy MP, ...
  • Bontempi IA, Vicco MH, Cabrera G, Villar SR, González FB, ...
  • Sjölander A, Baldwin TM, Curtis JM, Bengtsson KL, Handman E. ...
  • Papadopoulou G, Karagouni E, Dotsika E. ISCOMs vaccine against experimental ...
  • Kensil CR. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug ...
  • Rönnberg B, Fekadu M, Morein B. Adjuvant activity of non-toxic ...
  • Drane D, Pearse M. The ISCOMATRIX adjuvant. In: Schijns VE, ...
  • نمایش کامل مراجع